The Bioidentical Hormone Lab Panel — What Each Number Actually Means

A comprehensive hormone panel for women contains more than one number. It contains a pattern. Individual values matter — but it is the relationship between estradiol, progesterone, testosterone, SHBG, thyroid markers, adrenal function, and metabolic indicators that tells the actual clinical story. Understanding what each analyte measures and what its clinical significance is allows patients to engage meaningfully with the interpretation.

Estradiol (E2)

Estradiol is the primary estrogen in premenopausal and perimenopausal women and the estrogen most relevant to hormone replacement in post-menopausal patients. It affects mood, cognition, cardiovascular health, bone density, skin thickness, libido, and vaginal tissue integrity.

In premenopausal women, estradiol fluctuates dramatically across the cycle — from as low as 20-40 pg/mL in the early follicular phase to over 200-400 pg/mL at the mid-cycle surge. The appropriate interpretation depends entirely on where in the cycle the measurement is taken.

In post-menopausal women, estradiol typically falls below 30 pg/mL. Hormone therapy targets levels that resolve symptoms and protect long-term health — typically in the 50-150 pg/mL range, individualized by clinical response.

Symptoms of estradiol deficiency: hot flashes, vaginal dryness, sleep disruption, mood instability, cognitive fogging, and accelerated skin aging. Symptoms of estradiol excess: breast tenderness, bloating, fluid retention, and mood changes that can include anxiety and irritability.

Progesterone

Progesterone in premenopausal women is produced primarily by the corpus luteum after ovulation. Its measurement is most meaningful in the luteal phase (days 18-22 of a 28-day cycle). Low luteal phase progesterone confirms inadequate progesterone production — anovulatory cycles produce very low progesterone regardless of cycle timing.

In perimenopausal women, progesterone is typically the first hormone to decline — before estrogen falls significantly. This is why perimenopausal symptoms often precede what standard labs would identify as "estrogen deficiency."

Symptoms of progesterone deficiency: sleep disruption (particularly early waking), anxiety, mood volatility, breast tenderness, bloating, and irregular or heavy cycles. Progesterone restoration often dramatically resolves these symptoms — and the dose required is far lower than many patients and clinicians expect.

Total and free testosterone

Testosterone is not exclusively a male hormone. Women produce testosterone in the ovaries and adrenal glands, and its decline — which accelerates during the perimenopausal transition — is directly associated with reduced energy, libido, arousal capacity, muscle mass, and mood stability.

Testosterone in women is typically the first sex hormone to decline in perimenopause — often years before significant estrogen deficiency is apparent. Free testosterone (not total) is the clinically relevant fraction. SHBG elevation — which rises with age and oral estrogen therapy — can render total testosterone values misleadingly normal while free testosterone is functionally deficient.

DHEA-S

DHEA-sulfate (DHEA-S) is the primary adrenal androgen and a precursor to both estrogen and testosterone. It peaks in the mid-20s and declines progressively with age. Low DHEA-S contributes to fatigue, reduced libido, cognitive sluggishness, and impaired immune function. Adrenal insufficiency or long-term stress-related adrenal dysregulation produces lower DHEA-S values that are often seen in clinically exhausted patients.

FSH and LH

Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are pituitary hormones that drive the ovarian cycle. As the ovaries become less responsive with age, the pituitary increases FSH production in an attempt to stimulate follicular development.

Elevated FSH is the hallmark laboratory marker of menopausal transition. Post-menopausal FSH is consistently above 30-40 IU/L. During perimenopause, FSH may be elevated on some draws and normal on others — which is why a single FSH measurement can be misleading in a still-cycling woman.

LH elevation parallels FSH elevation in menopause and helps distinguish ovarian failure (primary hypogonadism) from pituitary or hypothalamic dysfunction (secondary hypogonadism).

SHBG

Sex hormone-binding globulin binds to estradiol and testosterone, reducing their biological availability. High SHBG — driven by age, oral estrogen use, or liver factors — can mask functional hormone deficiency even when total hormone values appear normal. The free fractions of estradiol and testosterone are what matter at the receptor level.

Thyroid panel

The thyroid regulates the metabolic rate of every cell in the body. Thyroid dysfunction — even at subclinical levels — produces symptoms that overlap extensively with hormone deficiency: fatigue, weight gain, cognitive slowing, mood changes, and sleep disruption.

A complete thyroid panel includes TSH, free T3, free T4, and in some cases reverse T3. TSH alone misses the full picture. Free T3 is the most metabolically active thyroid hormone. Reverse T3 is an inactive form that competes with T3 at the receptor — elevated reverse T3 can produce thyroid deficiency symptoms even with a normal free T3.

Fasting insulin and glucose

Insulin resistance is a metabolic state that drives fat storage, weight gain resistance, and cardiovascular risk — and it is frequently underdiagnosed because standard glucose screening does not detect early insulin resistance. Fasting insulin (rather than glucose alone) is more sensitive to early insulin resistance. HOMA-IR (calculated from fasting glucose and insulin) quantifies the degree of insulin resistance and guides dietary and pharmacological intervention.

Cortisol

Morning serum cortisol or a four-point salivary/dried urine cortisol assessment reveals the cortisol pattern across the day. Cortisol governs the stress response, energy architecture, immune function, and — when chronically elevated — visceral fat deposition, sleep disruption, and mood instability. An appropriate morning cortisol with adequate diurnal decline is part of the metabolic foundation that hormone therapy is built upon.

What optimal looks like

"Normal" reference ranges capture the population distribution — including people who are symptomatic at their current level. Optimal is a different threshold: the value at which a given patient experiences best function and fewest symptoms. The pattern of values together, interpreted in the context of clinical symptoms and history, is the foundation of meaningful hormone therapy. A number in isolation rarely tells the full story.